Investigational drug · Phase 2
LHP588
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alzheimer Disease, Alzheimer Disease Due to P. Gingivalis.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "LHP588"
First trial start
2025
Feb 17, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LHP588", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alzheimer Disease
- Alzheimer Disease Due to P. Gingivalis
Approved drugs for the same conditions: Alzheimer's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "LHP588" as an intervention, largest first.
- Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's DiseasePivotal-lookingRecruiting
Lighthouse Pharmaceuticals, Inc.Industry
NCT06847321 · 300 participants (planned) · Start Feb 17, 2025 · Primary completion Jan 31, 2029
Drug: LHP588; LHP588 and 1 more · For: Alzheimer Disease; Alzheimer Disease Due to P. Gingivalis
Sites: Phoenix, Arizona; Scottsdale, Arizona; Murrieta, California · 39 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Gingipains as macromolecular mediators at the periodontal-brain interface: Mechanistic, diagnostic, and therapeutic evidence in Alzheimer's and Parkinson's diseases.
Dhar I, Gupta S, Mishra R, et al. · Int J Biol Macromol 2026
Also in development for Alzheimer Disease
- KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials
Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder
- ITI-1284JNJ-99245354Phase 36 trials
Intra-Cellular Therapies, Inc. · Generalized Anxiety Disorder, Agitation Associated With Alzheimer's Dementia, Psychotic Disorders
- AXS-05dextromethorphan-bupropionPhase 33 trials
Axsome Therapeutics, Inc. · Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Smoking Cessation
- MasitinibAB1010Phase 33 trials
AB Science · Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease
- SPG302TazbentetolPhase 33 trials
Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis
- Combined metabolic activatorsPhase 32 trials
ScandiBio Therapeutics AB · Alzheimer Disease, Gout Disease
- DMB-IINN: Latrepirdine, DimebonPhase 32 trials
Bigespas LTD · Alzheimer Type Dementia, Alzheimer Disease, Dementia of Alzheimer Type
- AR1001Phase 31 trial
AriBio Co., Ltd. · Alzheimer Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.